Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT06943755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06943755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
Lead sponsor
Exelixis
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 21, 2025
Completion date
June 30, 2029
Enrollment
440 (estimated)
Sites
131

Conditions

As the registry lists them; a condition with its own page is linked.

extra-pancreatic neuroendocrine tumor (epnet), pancreatic neuroendocrine tumor (pnet)